Mail

CSL.AX - CSL Limited

ASX - ASX Delayed Price. Currency in AUD

338.31

-2.69 (-0.79%)

At close: 3:59PM AEDT

Stock chart is not supported by your current browser

Previous Close	341.00
Open	339.42
Bid	338.60 x 0
Ask	311.25 x 0
Day's Range	337.03 - 342.75
52 Week Range	184.03 - 342.75
Volume	752,881
Avg. Volume	779,234

Market Cap	153.553B
Beta (5Y Monthly)	0.29
PE Ratio (TTM)	76.59
EPS (TTM)	4.42
Earnings Date	Feb 12, 2020
Forward Dividend & Yield	2.87 (0.87%)
Ex-Dividend Date	Mar 11, 2020
1y Target Est	151.95

All

News

Press Releases

Thomson Reuters StreetEvents
Edited Transcript of CSL.AX earnings conference call or presentation 12-Feb-20 12:00am GMT
Half Year 2020 CSL Ltd Earnings Presentation
PR Newswire
University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware
Researchers at the University of Pittsburgh and the University of Delaware have been awarded funding and support to accelerate their search for new medicines through an ongoing partnership between global biotechnology leader CSL Behring and the University City Science Center.
PR Newswire
PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)
Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin Intravenous (Human),10% Liquid) orphan-drug designation as an investigational therapy in the treatment of Systemic Sclerosis (SSc). SSc is a chronic and potentially life-threatening autoimmune disorder characterized by a build-up of scar tissue (fibrosis) in the skin and other organs.1 It affects approximately 100,000 people in the U.S.2 There are currently no FDA-approved, disease-modifying treatments to stop or reverse the overall course of the disease.
Reuters
Australia's CSL posts 8% rise in H1 profit; raises FY outlook
Australian biotech company CSL Ltd on Wednesday posted an 8% rise in first-half profit and raised its earnings forecast for the full year, helped by strong demand for its immunoglobulin (IG) products. The company, which makes treatments for blood-related diseases and vaccines for influenza, posted a net profit of $1.25 billion for the six months ended Dec. 31, compared with $1.16 billion a year earlier. CSL raised its after-tax net profit forecast for the full year to a range of $2.11 billion to $2.17 billion at constant currency.
Reuters
Australia shares end higher on broad-based gains, NZ up over 1%
CNW Group
HAEGARDA® is now available in the province of Québec for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients
HAEGARDA® is now available in the province of Québec for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients
PR Newswire
Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. Food and Drug Administration (FDA) has approved AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1).1 AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.2
Simply Wall St.
Is CSL Limited's (ASX:CSL) 37% ROE Better Than Average?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
PR Newswire
Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity
Forbes Magazine today named CSL Behring among its Best Employers for Diversity 2020.
PR Newswire
Researchers decipher a new way that immune cells detect infections and cancers
Peer reviewed: ScienceProject funding: Australian Research Council, National Health and Medical Research Council, Cancer Council Victoria, the Victorian Cancer Agency and CSL LimitedThis study used in-vitro models
PR Newswire
Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference
Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will present at the 38th annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
Simply Wall St.
Investors Who Bought CSL (ASX:CSL) Shares Five Years Ago Are Now Up 222%
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
PR Newswire
New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
Seqirus announced today results from a prospective, cluster-randomized trial led by a team of researchers from Brown University that showed FLUAD®, an adjuvanted trivalent influenza vaccine (aTIV), was more effective than standard non-adjuvanted trivalent influenza vaccine (TIV) in reducing the risk of all-cause hospitalizations, as well as hospitalization for influenza and pneumonia, in adults 65 years and older living in United States (U.S.) nursing homes during the 2016/17 influenza season.1 These findings were presented at the recent National Foundation for Infectious Diseases (NFID) 2019 Clinical Vaccinology Course (CVC), which took place in Washington, D.C.
PR Newswire
HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. CIDP is a rare autoimmune disorder that affects the peripheral nerves and has the potential to cause significant disability.
Thomson Reuters StreetEvents
Edited Transcript of CSL.AX earnings conference call or presentation 14-Aug-19 1:00am GMT
Full Year 2019 CSL Ltd Earnings Call
Simply Wall St.
Does CSL Limited's (ASX:CSL) CEO Pay Matter?
In 2013 Paul Perreault was appointed CEO of CSL Limited (ASX:CSL). This analysis aims first to contrast CEO...
PR Newswire
Harvard Business Review Names CSL's Paul Perreault Among Best Performing CEOs in the World
KING OF PRUSSIA, Pa., Oct. 24, 2019 /PRNewswire/ -- Harvard Business Review (HBR) today named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world for 2019. Unlike rankings that are based on subjective evaluations or short-term metrics, the CEO 100 list relies on objective performance measures over a chief executive's entire tenure, according to HBR. This is Perreault's first time on the CEO 100 at no. 83.
Simply Wall St.
Does CSL (ASX:CSL) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Moody's
CSLB Holdings Inc. -- Moody's announces completion of a periodic review of ratings of CSL Limited
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of CSL Limited and other ratings that are associated with the same analytical unit. "IMPORTANT NOTICE: MOODY'S RATINGS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
PR Newswire
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
HOLLY SPRINGS, N.C. , Sept. 26, 2019 /PRNewswire/ -- Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans ...
Simply Wall St.
What Kind Of Investor Owns Most Of CSL Limited (ASX:CSL)?
The big shareholder groups in CSL Limited (ASX:CSL) have power over the company. Large companies usually have...
Simply Wall St.
CSL Limited (ASX:CSL): Is It A Good Long Term Opportunity?
In August 2019, CSL Limited (ASX:CSL) released its latest earnings announcement, which showed that the company gained...
PR Newswire
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
SUMMIT, N.J. , Aug. 31, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in ...
PR Newswire
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
SUMMIT, N.J. , Aug. 30, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from ...